<DOC>
	<DOCNO>NCT01863238</DOCNO>
	<brief_summary>This study design evaluate risk cataract ( lens opacity ) describe best correct distance vision ( glasses/contacts wear ) pediatric patient Cystic Fibrosis 11 year age young time ivacaftor treatment initiation receive plan receive commercially-available ivacaftor US .</brief_summary>
	<brief_title>An Ocular Safety Study Ivacaftor-Treated Pediatric Patients 11 Years Age Younger With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Subject must 11 year age young time treatment initiation ivacaftor ( part clinical trial ) commerciallyavailable ivacaftor . 2 . Subject must reside US receive plan receive commerciallyavailable ivacaftor . 1 . Subject enrol ivacaftor clinical study ivacaftor exposure mandate protocol . 2 . Subject receive surgery cataract</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>